The HIV pandemic is one of the greatest ongoing threats to health and development, over 30 years past its recognition. The NIAID-funded Clinical Trials Networks have played critical roles in the coordinated response to key research questions in the HIV/AIDS field. The proposed Vanderbilt Clinical Trials Unit (CTU) is a partnership between Vanderbilt University and Washington University, comprising three top-performing incumbent Clinical Research Sites (CRSs) that span the therapeutics mission of the AIDS Clinical Trials Group (ACTG) and the vaccine mission of the HIV Vaccine Trials Network (HVTN). This builds upon the already established partnership between the Vanderbilt Therapeutics CRS and the Vanderbilt Vaccine CRS, and adds a new partnership with the Washington University Therapeutics CRS. The latter two sites have been members of the HVTN and ACTG since the inception of these Networks in 1987-1988. The leaders of this CTU have made high-impact, unique scientific and programmatic contributions to the Networks in areas that include human genomics and neurological aspects of HIV disease. Moving forward this CTU will continue its track record of programmatic impact by leveraging Vanderbilt's institutional strength in biomedical informatics to implement flexible, real-time, shareable informatics tools to optimize CTU performance. This CTU also benefits from close ties to other major NIH programs including Vanderbilt's roles as Coordinating Center for the nationwide network of approximately 60 Clinical and Translational Science Awards (CTSA), for the seven worldwide regions of the NIAID-sponsored International Epidemiologic Databases to Evaluate AIDS (leDEA), and for the seven countries of leDEA's Latin American region. During the proposed finding period the Vanderbilt CTU will make substantial contributions to the ACTG's scientific priorities focused on HIV/AIDS, tuberculosis, and viral hepatitis, and will make substantial contributions to the HVTN's major scientific priority of developing and testing a safe and effective vaccine for HIV.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RCU-A (S5))
Program Officer
Welsch, Sue A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Riddler, Sharon A; Zheng, Lu; Durand, Christine M et al. (2018) Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. Open Forum Infect Dis 5:ofy242
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Li, Shuying S; Kochar, Nidhi K; Elizaga, Marnie et al. (2017) DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. Clin Vaccine Immunol 24:
Clifford, David B (2017) HIV-associated neurocognitive disorder. Curr Opin Infect Dis 30:117-122
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111

Showing the most recent 10 out of 111 publications